Last reviewed · How we verify
The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation
This study aims to explore the safety and tolerability of a single dose of psilocybin (25mg) administered under supportive conditions to adult participants with TRD and chronic suicidal ideation
Details
| Lead sponsor | Sheppard Pratt Health System |
|---|---|
| Phase | PHASE2 |
| Status | COMPLETED |
| Enrolment | 20 |
| Start date | Mon Mar 28 2022 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Mon May 12 2025 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Treatment Resistant Depression
- Suicidal Ideation
Interventions
- Psilocybin
Countries
United States